| Regents Of The University Of Michigan Dental Faculty Associates | |
|
1011 N University Ave Ann Arbor MI 48109-1078 | |
| (734) 764-3155 | |
| (734) 615-4784 |
| Full Name | Regents Of The University Of Michigan Dental Faculty Associates |
|---|---|
| Speciality | Dentist |
| Location | 1011 N University Ave, Ann Arbor, Michigan |
| Authorized Official Name and Position | Peter J Polverini (DEAN, UNIV OF MI SCHOOL OF DENTISTR) |
| Authorized Official Contact | 7347649185 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Regents Of The University Of Michigan Dental Faculty Associates 1011 N University Ave Ann Arbor MI 48109-1078 Ph: (734) 764-9185 | Regents Of The University Of Michigan Dental Faculty Associates 1011 N University Ave Ann Arbor MI 48109-1078 Ph: (734) 764-3155 |
| NPI Number | 1932279882 |
|---|---|
| Provider Enumeration Date | 11/08/2006 |
| Last Update Date | 08/20/2008 |
| Medicare PECOS PAC ID | 8729043534 |
|---|---|
| Medicare Enrollment ID | O20041122000230 |
News Archive
Valtronic develops partnerships built on the creation of innovative ideas, technology, and positive outcomes for all.
Relapsing-Remitting Multiple Sclerosis (RRMS) patients have been anticipating the availability of new oral therapies being developed to treat their specific condition. Among the string of oral therapies entering the market is Novartis' Gilenya, which recently became available for use following receipt of FDA approval in late September. One-third of MS patients are aware the new oral agents are under development and there is substantial interest within this group to seek further information through physicians and other sources, according to new research by GfK HealthCare.
VolitionRx Limited today announced the Company's first CE Mark for its blood-based diagnostic assay, NuQ X001S, for detection of colorectal cancer. The NuQ test utilizes the Company's proprietary Nucleosomics technology platform, which identifies and analyses fragments of chromosomes, called nucleosomes, circulating within the blood for the presence of epigenetic cancer signals.
Hospital workers are asking the same questions about the safety and necessity of flu vaccines as the general public, according to a survey conducted by the American Society of Health-System Pharmacists (ASHP).
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932279882 | NPI | - | NPPES |
| 970H110770 | Other | MI | BCBS OF MI ORALSURGERY |
| XX19411 | Other | MI | HEALTH PLUS OF MI |
| 1006664 | Other | MI | MCLAREN ADVANTAGE |
| 2667609 | Medicaid | OH | |
| 43-20001 | Other | MI | PHP OF MI |
| 43-28004 | Other | MI | PHP OF MI |
| 4504346 | Medicaid | MI | |
| 190H110980 | Other | MI | BCBS OF MI MEDSURG # |
| 025748 | Other | MI | MIDWEST HEALTH |
| 1476671 | Other | MI | UNITED CONCORDIA |
| 4504373 | Medicaid | MI | |
| 88054 | Other | MI | DELTA DENTAL OF MI - GENL |
| D800363 | Other | MI | BCBS OF MI GENLDENTIST |
| QMXPR0014549 | Other | MI | MOLINA HEALTHCARE |
| Provider Name | Brent B Ward |
|---|---|
| Provider Type | Practitioner - Maxillofacial Surgery |
| Provider Identifiers | NPI Number: 1073611794 PECOS PAC ID: 5799734505 Enrollment ID: I20050119000705 |
News Archive
Valtronic develops partnerships built on the creation of innovative ideas, technology, and positive outcomes for all.
Relapsing-Remitting Multiple Sclerosis (RRMS) patients have been anticipating the availability of new oral therapies being developed to treat their specific condition. Among the string of oral therapies entering the market is Novartis' Gilenya, which recently became available for use following receipt of FDA approval in late September. One-third of MS patients are aware the new oral agents are under development and there is substantial interest within this group to seek further information through physicians and other sources, according to new research by GfK HealthCare.
VolitionRx Limited today announced the Company's first CE Mark for its blood-based diagnostic assay, NuQ X001S, for detection of colorectal cancer. The NuQ test utilizes the Company's proprietary Nucleosomics technology platform, which identifies and analyses fragments of chromosomes, called nucleosomes, circulating within the blood for the presence of epigenetic cancer signals.
Hospital workers are asking the same questions about the safety and necessity of flu vaccines as the general public, according to a survey conducted by the American Society of Health-System Pharmacists (ASHP).
› Verified 3 days ago
| Provider Name | Laurie Mccauley |
|---|---|
| Provider Type | Practitioner - Oral Surgery |
| Provider Identifiers | NPI Number: 1598898744 PECOS PAC ID: 9739120627 Enrollment ID: I20050520000651 |
News Archive
Valtronic develops partnerships built on the creation of innovative ideas, technology, and positive outcomes for all.
Relapsing-Remitting Multiple Sclerosis (RRMS) patients have been anticipating the availability of new oral therapies being developed to treat their specific condition. Among the string of oral therapies entering the market is Novartis' Gilenya, which recently became available for use following receipt of FDA approval in late September. One-third of MS patients are aware the new oral agents are under development and there is substantial interest within this group to seek further information through physicians and other sources, according to new research by GfK HealthCare.
VolitionRx Limited today announced the Company's first CE Mark for its blood-based diagnostic assay, NuQ X001S, for detection of colorectal cancer. The NuQ test utilizes the Company's proprietary Nucleosomics technology platform, which identifies and analyses fragments of chromosomes, called nucleosomes, circulating within the blood for the presence of epigenetic cancer signals.
Hospital workers are asking the same questions about the safety and necessity of flu vaccines as the general public, according to a survey conducted by the American Society of Health-System Pharmacists (ASHP).
› Verified 3 days ago
| Provider Name | Sean P Edwards |
|---|---|
| Provider Type | Practitioner - Maxillofacial Surgery |
| Provider Identifiers | NPI Number: 1952313892 PECOS PAC ID: 7214932011 Enrollment ID: I20060929000385 |
News Archive
Valtronic develops partnerships built on the creation of innovative ideas, technology, and positive outcomes for all.
Relapsing-Remitting Multiple Sclerosis (RRMS) patients have been anticipating the availability of new oral therapies being developed to treat their specific condition. Among the string of oral therapies entering the market is Novartis' Gilenya, which recently became available for use following receipt of FDA approval in late September. One-third of MS patients are aware the new oral agents are under development and there is substantial interest within this group to seek further information through physicians and other sources, according to new research by GfK HealthCare.
VolitionRx Limited today announced the Company's first CE Mark for its blood-based diagnostic assay, NuQ X001S, for detection of colorectal cancer. The NuQ test utilizes the Company's proprietary Nucleosomics technology platform, which identifies and analyses fragments of chromosomes, called nucleosomes, circulating within the blood for the presence of epigenetic cancer signals.
Hospital workers are asking the same questions about the safety and necessity of flu vaccines as the general public, according to a survey conducted by the American Society of Health-System Pharmacists (ASHP).
› Verified 3 days ago
| Provider Name | Sharon Aronovich |
|---|---|
| Provider Type | Practitioner - Maxillofacial Surgery |
| Provider Identifiers | NPI Number: 1871777326 PECOS PAC ID: 2163576885 Enrollment ID: I20110927000572 |
News Archive
Valtronic develops partnerships built on the creation of innovative ideas, technology, and positive outcomes for all.
Relapsing-Remitting Multiple Sclerosis (RRMS) patients have been anticipating the availability of new oral therapies being developed to treat their specific condition. Among the string of oral therapies entering the market is Novartis' Gilenya, which recently became available for use following receipt of FDA approval in late September. One-third of MS patients are aware the new oral agents are under development and there is substantial interest within this group to seek further information through physicians and other sources, according to new research by GfK HealthCare.
VolitionRx Limited today announced the Company's first CE Mark for its blood-based diagnostic assay, NuQ X001S, for detection of colorectal cancer. The NuQ test utilizes the Company's proprietary Nucleosomics technology platform, which identifies and analyses fragments of chromosomes, called nucleosomes, circulating within the blood for the presence of epigenetic cancer signals.
Hospital workers are asking the same questions about the safety and necessity of flu vaccines as the general public, according to a survey conducted by the American Society of Health-System Pharmacists (ASHP).
› Verified 3 days ago
| Provider Name | Amy M Chin |
|---|---|
| Provider Type | Practitioner - Maxillofacial Surgery |
| Provider Identifiers | NPI Number: 1114144581 PECOS PAC ID: 2668607698 Enrollment ID: I20131029002077 |
News Archive
Valtronic develops partnerships built on the creation of innovative ideas, technology, and positive outcomes for all.
Relapsing-Remitting Multiple Sclerosis (RRMS) patients have been anticipating the availability of new oral therapies being developed to treat their specific condition. Among the string of oral therapies entering the market is Novartis' Gilenya, which recently became available for use following receipt of FDA approval in late September. One-third of MS patients are aware the new oral agents are under development and there is substantial interest within this group to seek further information through physicians and other sources, according to new research by GfK HealthCare.
VolitionRx Limited today announced the Company's first CE Mark for its blood-based diagnostic assay, NuQ X001S, for detection of colorectal cancer. The NuQ test utilizes the Company's proprietary Nucleosomics technology platform, which identifies and analyses fragments of chromosomes, called nucleosomes, circulating within the blood for the presence of epigenetic cancer signals.
Hospital workers are asking the same questions about the safety and necessity of flu vaccines as the general public, according to a survey conducted by the American Society of Health-System Pharmacists (ASHP).
› Verified 3 days ago
| Provider Name | Hsiao Hsin Sung |
|---|---|
| Provider Type | Practitioner - Oral Surgery |
| Provider Identifiers | NPI Number: 1205191590 PECOS PAC ID: 8729392063 Enrollment ID: I20150731014301 |
News Archive
Valtronic develops partnerships built on the creation of innovative ideas, technology, and positive outcomes for all.
Relapsing-Remitting Multiple Sclerosis (RRMS) patients have been anticipating the availability of new oral therapies being developed to treat their specific condition. Among the string of oral therapies entering the market is Novartis' Gilenya, which recently became available for use following receipt of FDA approval in late September. One-third of MS patients are aware the new oral agents are under development and there is substantial interest within this group to seek further information through physicians and other sources, according to new research by GfK HealthCare.
VolitionRx Limited today announced the Company's first CE Mark for its blood-based diagnostic assay, NuQ X001S, for detection of colorectal cancer. The NuQ test utilizes the Company's proprietary Nucleosomics technology platform, which identifies and analyses fragments of chromosomes, called nucleosomes, circulating within the blood for the presence of epigenetic cancer signals.
Hospital workers are asking the same questions about the safety and necessity of flu vaccines as the general public, according to a survey conducted by the American Society of Health-System Pharmacists (ASHP).
› Verified 3 days ago
| Provider Name | Geoffrey E Gerstner |
|---|---|
| Provider Type | Practitioner - Dentist |
| Provider Identifiers | NPI Number: 1508232554 PECOS PAC ID: 2365782489 Enrollment ID: I20190327000482 |
News Archive
Valtronic develops partnerships built on the creation of innovative ideas, technology, and positive outcomes for all.
Relapsing-Remitting Multiple Sclerosis (RRMS) patients have been anticipating the availability of new oral therapies being developed to treat their specific condition. Among the string of oral therapies entering the market is Novartis' Gilenya, which recently became available for use following receipt of FDA approval in late September. One-third of MS patients are aware the new oral agents are under development and there is substantial interest within this group to seek further information through physicians and other sources, according to new research by GfK HealthCare.
VolitionRx Limited today announced the Company's first CE Mark for its blood-based diagnostic assay, NuQ X001S, for detection of colorectal cancer. The NuQ test utilizes the Company's proprietary Nucleosomics technology platform, which identifies and analyses fragments of chromosomes, called nucleosomes, circulating within the blood for the presence of epigenetic cancer signals.
Hospital workers are asking the same questions about the safety and necessity of flu vaccines as the general public, according to a survey conducted by the American Society of Health-System Pharmacists (ASHP).
› Verified 3 days ago
| Provider Name | Chia-cheng Li |
|---|---|
| Provider Type | Practitioner - Dentist |
| Provider Identifiers | NPI Number: 1588900518 PECOS PAC ID: 6507085545 Enrollment ID: I20190606002368 |
News Archive
Valtronic develops partnerships built on the creation of innovative ideas, technology, and positive outcomes for all.
Relapsing-Remitting Multiple Sclerosis (RRMS) patients have been anticipating the availability of new oral therapies being developed to treat their specific condition. Among the string of oral therapies entering the market is Novartis' Gilenya, which recently became available for use following receipt of FDA approval in late September. One-third of MS patients are aware the new oral agents are under development and there is substantial interest within this group to seek further information through physicians and other sources, according to new research by GfK HealthCare.
VolitionRx Limited today announced the Company's first CE Mark for its blood-based diagnostic assay, NuQ X001S, for detection of colorectal cancer. The NuQ test utilizes the Company's proprietary Nucleosomics technology platform, which identifies and analyses fragments of chromosomes, called nucleosomes, circulating within the blood for the presence of epigenetic cancer signals.
Hospital workers are asking the same questions about the safety and necessity of flu vaccines as the general public, according to a survey conducted by the American Society of Health-System Pharmacists (ASHP).
› Verified 3 days ago
News Archive
Valtronic develops partnerships built on the creation of innovative ideas, technology, and positive outcomes for all.
Relapsing-Remitting Multiple Sclerosis (RRMS) patients have been anticipating the availability of new oral therapies being developed to treat their specific condition. Among the string of oral therapies entering the market is Novartis' Gilenya, which recently became available for use following receipt of FDA approval in late September. One-third of MS patients are aware the new oral agents are under development and there is substantial interest within this group to seek further information through physicians and other sources, according to new research by GfK HealthCare.
VolitionRx Limited today announced the Company's first CE Mark for its blood-based diagnostic assay, NuQ X001S, for detection of colorectal cancer. The NuQ test utilizes the Company's proprietary Nucleosomics technology platform, which identifies and analyses fragments of chromosomes, called nucleosomes, circulating within the blood for the presence of epigenetic cancer signals.
Hospital workers are asking the same questions about the safety and necessity of flu vaccines as the general public, according to a survey conducted by the American Society of Health-System Pharmacists (ASHP).
› Verified 3 days ago
Blossom Pediatric Dentistry & Orthodontics Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 3100 Eisenhower Parkway, Suite 200, Ann Arbor, MI 48108 Phone: 734-971-3368 Fax: 734-971-3979 | |
Endodontic Associates Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 315 E Eisenhower Pkwy, #220, Ann Arbor, MI 48108 Phone: 734-761-3166 | |
Arbor Lodge Dental Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 2385 S Huron Pkwy, Ann Arbor, MI 48104 Phone: 734-971-1517 | |
A2 Endodontics Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 760 W Eisenhower Pkwy Ste 210, Ann Arbor, MI 48103 Phone: 734-330-2205 | |
James D Herter Dds, Pc Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 1901 Pauline Blvd, Ann Arbor, MI 48103 Phone: 734-663-6056 | |
Regina M. Dailey, Dmd Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 221 N Ingalls St, Ann Arbor, MI 48104 Phone: 734-996-0055 Fax: 734-996-5934 | |
Gloria James Kerry, D.d.s., M.s. Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 3250 Plymouth Rd Ste 104, Ann Arbor, MI 48105 Phone: 734-995-0515 Fax: 734-995-1299 |